Charles River (CRL) and Toxys announced a collaboration that offers Charles River’s clients access to ReproTracker, a human stem cell-based in vitro assay that rapidly and reliably identifies developmental toxicity hazards of new drugs and chemicals.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRL:
- Charles River upgraded to Outperform from Market Perform at William Blair
- Charles River price target raised to $200 from $190 at Evercore ISI
- Nike upgraded, RH downgraded: Wall Street’s top analyst calls
- Charles River upgraded to Overweight from Equal Weight at Barclays
- Charles River Labs: Navigating Leadership Changes and Market Challenges with a Hold Rating